Chinese drug-related stocks stumbled after a report that the Trump administration has been discussing major restrictions on medicines from the Asian nation. The Hang Seng Biotech Index dropped as much as 8.6%, the most in five months, before paring much of the loss. A draft executive order aims to impose tough scrutiny on licensing deals for experimental drugs with Chinese firms as part of an effort to boost the domestic US pharmaceutical sector, according to the New York Times report. Most Read from Bl ...